Peptides and Liver Detox: What the Science Actually Says
Written by NorthPeptide Research Team | Reviewed January 2, 2026
The Liver and Peptide Research
The liver is the body’s primary detoxification organ. It filters blood, metabolizes drugs and toxins, produces bile, and plays a central role in metabolism. Given its workload, it is also highly vulnerable to damage from alcohol, medications, metabolic disease, and environmental toxins. Researchers have studied several peptides and peptide-adjacent compounds for their potential to protect or support liver function.
It is worth being precise: “detox” as a marketing concept is largely unsupported by science. The liver detoxifies continuously and does not need help under normal conditions. What research does examine is whether specific compounds can protect liver cells from damage, reduce inflammation, or support recovery after injury.
BPC-157: The Gastrointestinal Peptide with Liver Effects
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It has been extensively studied in rodent models for its effects on gastrointestinal healing, wound repair, and organ protection.
Several studies have examined BPC-157 in the context of liver damage. Researchers have found that it can reduce liver damage markers (ALT, AST) in models of toxin-induced hepatotoxicity. It appears to modulate nitric oxide signaling and activate cytoprotective pathways. In one series of studies, BPC-157 showed protective effects against alcohol-induced liver damage and NSAID-induced gastrointestinal injury.
Glutathione: The Master Antioxidant
Glutathione is a tripeptide (glycine-cysteine-glutamate) produced naturally in the liver. It is the liver’s most important endogenous antioxidant. The liver uses glutathione to neutralize reactive oxygen species generated during phase I and phase II detoxification reactions.
Supplemental glutathione has been studied for liver conditions including NAFLD, alcoholic liver disease, and drug-induced liver injury. Research on intravenous glutathione shows more consistent results than oral administration due to poor oral bioavailability. NAC (N-acetylcysteine) is often used to boost liver glutathione levels and is an established clinical treatment for acetaminophen overdose.
NAD+: Cellular Energy and Liver Metabolism
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential for cellular energy metabolism. NAD+ levels decline with age and are depleted by chronic alcohol use, inflammation, and metabolic stress. The liver is one of the most metabolically active organs and heavily depends on NAD+ for ATP production and SIRT1/SIRT3 activity.
Research in rodent models shows that NAD+ precursor supplementation can reduce alcohol-induced liver fat accumulation, lower inflammatory markers, and improve mitochondrial function in hepatocytes. Clinical research in humans is still early but growing.
What the Research Does Not Support
Despite promising preclinical data, there is no human clinical evidence that any peptide “detoxifies” the liver in a meaningful way beyond what the liver already does. BPC-157 has never been tested in human clinical trials for liver indications. Glutathione oral bioavailability remains a challenge. Researchers should approach this area with appropriate skepticism about extrapolating animal data to human outcomes.
Protocol Design Considerations
When designing experiments involving these compounds and liver outcomes, key variables include: route of administration, timing relative to the hepatotoxic insult, dose-response relationships, and which liver damage biomarkers are being tracked (ALT, AST, bilirubin, liver histology).
Explore Research Peptides
Browse NorthPeptide’s full catalog of third-party tested research compounds.
Written by the NorthPeptide Research Team
| PMID | Authors | Year | Key Finding |
|---|---|---|---|
| 10223677 | Sikiric P et al. | 1999 | BPC-157 protects against cysteamine-induced duodenal ulcer and liver lesion |
| 23093478 | Sikiric P et al. | 2012 | Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease and wound healing |
| 26721569 | Honda Y et al. | 2017 | Efficacy of glutathione for liver disease: RCT in NAFLD patients |
| 28167872 | Gariani K et al. | 2016 | Eliciting the mitochondrial unfolded protein response by NAD+ repletion reverses fatty liver disease |
| 28211357 | Trammell SA et al. | 2016 | Nicotinamide riboside is uniquely and orally bioavailable in healthy humans |
This content is intended for informational purposes only and is not medical advice. NorthPeptide products are for laboratory research use only and are not approved for human consumption. Always consult a qualified healthcare professional.